# STOMP

Source: https://onco.cc/trials/stomp-oligorecurrence/  
OnCo record `stomp-oligorecurrence` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Zapping the handful of spots that show up when prostate cancer comes back put off the day hormone therapy was needed, by about eight months, in a small trial.

## Summary

STOMP randomised 62 men with asymptomatic biochemical recurrence and three or fewer extracranial metastases on choline PET-CT to surveillance or metastasis-directed therapy of all detected lesions by surgery or stereotactic body radiotherapy. Randomisation was balanced on PSA doubling time (3 months or less against more than 3) and on nodal against non-nodal metastases. Androgen deprivation was started at symptomatic progression, progression to more than three metastases, or local progression of known metastases.

At a median 3 years (interquartile range 2.3 to 3.75), median androgen deprivation-free survival was 13 months (80 percent confidence interval 12 to 17) with surveillance and 21 months (80 percent confidence interval 14 to 29) with metastasis-directed therapy, hazard ratio 0.60 (80 percent confidence interval 0.40 to 0.90, log-rank p=0.11). The 80 percent confidence interval is what the trial was designed to report and is much wider than the conventional 95 percent.

Quality of life was similar between arms at baseline, 3 months and 1 year. Six men in the treatment arm had grade 1 toxicity and no grade 2 to 5 toxicity was observed.

STOMP is a signal, not a proof. It changed practice anyway, partly because PSMA PET made small-volume recurrence visible in far more men, and the phase 3 trials that should settle it are still running.

## Fields

- Kind: Trial
- Status: mixed
- Last checked: 2026-09-25
- Also known as: STOMP; Surveillance or Metastasis-directed Therapy for Oligometastatic Prostate cancer recurrence
- Registry id: NCT01558427
- Phase: 2
- Setting: Asymptomatic biochemical recurrence after treatment with curative intent, three or fewer extracranial metastases on choline PET-CT and serum testosterone above 50 ng/mL: surveillance against metastasis-directed therapy to all detected lesions by surgery or stereotactic body radiotherapy, with androgen deprivation-free survival as the primary endpoint
- Sponsor: Ghent University Hospital
- Enrolled: 62
- Result: Median androgen deprivation-free survival 21 months with metastasis-directed therapy against 13 months with surveillance (hazard ratio 0.60, 80 percent confidence interval 0.40 to 0.90, p=0.11); no grade 2 or worse toxicity.
- Outcomes: Androgen deprivation-free survival (median): Metastasis-directed therapy 21 months vs Surveillance 13 months, HR 0.6
- Replication: ORIOLE (54 men) found progression at 6 months in 19 percent after stereotactic radiotherapy against 61 percent under observation (p=0.005); no phase 3 trial has yet reported a survival benefit.

## Sources

- ClinicalTrials.gov NCT01558427: https://clinicaltrials.gov/study/NCT01558427
- STOMP (Journal of Clinical Oncology 2018): https://doi.org/10.1200/JCO.2017.75.4853

## Connected records

- cancers: [Biochemical recurrence of prostate cancer](https://onco.cc/cancers/prostate-bcr/), [Metastatic hormone-sensitive prostate cancer](https://onco.cc/cancers/prostate-mhspc/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- technologies: [Robotic & minimally invasive surgery](https://onco.cc/technologies/robotic-surgery/), [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/), [Stereotactic ablative radiotherapy for oligometastatic disease](https://onco.cc/technologies/sabr-oligometastases/)
- terms: [Androgen deprivation therapy (ADT)](https://onco.cc/terms/adt/), [Biochemical recurrence (BCR)](https://onco.cc/terms/biochemical-recurrence/), [Oligometastatic disease](https://onco.cc/terms/oligometastatic/), [PSA kinetics: PSA doubling time and PSA density](https://onco.cc/terms/psa-kinetics/)
- trials: [EMBARK](https://onco.cc/trials/embark/), [ORIOLE](https://onco.cc/trials/oriole/), [SABR-COMET: stereotactic ablative radiotherapy for oligometastatic cancer](https://onco.cc/trials/sabr-comet/)

---
JSON: https://onco.cc/api/v1/entities/stomp-oligorecurrence.json